New HPV vaccine aims to block more cancer types in early trial

NCT ID NCT06688058

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new vaccine called V540D, designed to protect against more types of human papillomavirus (HPV) than the current Gardasil 9 vaccine. The study involves 72 healthy adults and will compare the safety and immune response of V540D to Gardasil 9. The main goal is to see if V540D is safe and well-tolerated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: V540D (experimental HPV vaccine with adjuvant)
What this could lead to: If successful, this could lead to a vaccine that protects against more types of HPV than current options, potentially preventing more HPV-related cancers.
What could go wrong: This is an early Phase 1 trial with only 72 healthy adults, focused on safety and immune response. It is too soon to know if the vaccine will work in the real world or be better than existing vaccines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Alliance for Multispecialty Research, LLC ( Site 0003)

Kansas City, Missouri, 64114, United States
Alliance for Multispecialty Research, LLC ( Site 0004)

Knoxville, Tennessee, 37920, United States
Research Centers of America ( Hollywood ) ( Site 0001)

Hollywood, Florida, 33024, United States
Velocity Clinical Research, Savannah ( Site 0005)

Savannah, Georgia, 31406, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.